StockGuru News: NextGen (NXGB) Acquires Patent Application for Breast Cancer Stem Cell Treatment
LONDON, UNITED KINGDOM–Apr 8, 2008 — NextGen Bioscience, Inc., a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has acquired use, commercialisation and ownership rights of a patent application for the treatment of cancer from Oxon Life Science Inc. The patent application describes an improved method of identifying and purifying undifferentiated stem cells from solid breast carcinomas that are normally resistant to conventional therapies. The cancer stem cell is typically represented as a distinct population of cells within a tumour which may remain even if the rest of the tumour is…